LOS ANGELES–(BUSINESS WIRE)–Eyenuk, Inc., société mondiale de technologies et services médicaux basés sur l’intelligence artificielle (IA), qui se démarque en tant que leader dans le domaine des applications en situation réelle pour le dépistage ocul…
Category: Business
El AI Eye Screening System (sistema de exploración ocular vía IA), de Eyenuk, para retinopatía diabética demuestra un rendimiento excepcional en un ensayo clínico prospectivo, fundamental realizado en múltiples centros
LOS ÁNGELES–(BUSINESS WIRE)–Eyenuk, Inc., una compañía global de tecnología y servicios médicos vía inteligencia artificial (IA) y líder en aplicaciones en el mundo real para IA Eye Screening™, hoy anunció los resultados de su ensayo clínico prospect…
Allegro Ophthalmics to Present the Results of Its ALG-1007 Ex-U.S. Trial for Dry Eye Disease at the 2019 ASCRS•ASOA Annual Meeting
SAN JUAN CAPISTRANO, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/ASCRS?src=hash" target="_blank"gt;#ASCRSlt;/agt;–Allegro Ophthalmics announced that the results of its ALG-1007 ex-U.S. clinical t…
Sistema de avaliação ocular que faz uso de inteligência artificial da Eyenuk para retinopatia diabética demonstra excelente desempenho em um estudo clínico fundamental, prospectivo e multicêntrico
LOS ANGELES–(BUSINESS WIRE)–A Eyenuk, Inc., empresa de serviços e tecnologia médica que faz uso de inteligência artificial (artificial intelligence, AI) e líder em aplicações do mundo real para avaliação ocular usando AI Eye Screening™, anunciou hoje…
Samenvatting: Eyenuk’s AI-oogcontrolesysteem voor diabetische retinopathie toont uitzonderlijke prestaties in een prospectieve cruciale klinische studie
LOS ANGELES–(BUSINESS WIRE)–Eyenuk, Inc., een internationaal bedrijf op het gebied van kunstmatige intelligentie (AI) en medische technologie en services en de leider in real-world toepassingen voor AI Eye Screening™, heeft vandaag de resultaten beke…
Riassunto: Allotex annuncia l'inizio della fase finale dei suoi studi clinici sulla presbiopia
BOSTON–(BUSINESS WIRE)–Allotex, società privata con sede a Boston impegnata nello sviluppo di lenticoli TransForm Corneal Allograft (TCA) per il trattamento della presbiopia (necessità di occhiali da lettura) e dell’ipermetropia (ipometropia), è lieta di annunciare il trattamento di oltre 50 occhi nella prima fase dei suoi studi clinici. I lenticoli TCA vengono creati a partire da tessuto corneale umano naturale modellato grazie a una tecnologia brevettata e proprietaria ad alta precisione; i
Allotex meldet Beginn der letzten klinischen Studienphase zu Presbyopie
BOSTON–(BUSINESS WIRE)–Allotex, ein in Boston ansässiges Privatunternehmen, das das TransForm Corneal Allograft (TCA) zur Behandlung von Presbyopie (Lesebrille) und Hyperopie (Weitsichtigkeit) entwickelt, meldet die Durchführung von mehr als 50 Augen…
Allotex annonce le début de la phase finale des essais cliniques sur la presbytie
BOSTON–(BUSINESS WIRE)–Allotex, une société privée basée à Boston qui développe l’allogreffe cornéenne TransForm (TCA) pour le traitement de la presbytie (lunettes de lecture) et de l’hypermétropie (vision de loin), est ravie de pouvoir annoncer qu’une première phase des études cliniques a été consacrée à plus de 50 yeux. La TCA est créée à partir de tissu cornéen humain naturel qui a été façonné à l’aide d’une technologie brevetée et exclusive de haute précision. Ces lenticules façonnées son
Verseon Presents Oral Drug Candidate for Diabetic Eye Disease That Could Replace Eye Injections
FREMONT, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/biotech?src=hash" target="_blank"gt;#biotechlt;/agt;–Verseon presented their first DME development candidate at ARVO 2019. The candidate could…
Allotex Announces Commencement of Final Phase of Presbyopia Clinical Trials
BOSTON–(BUSINESS WIRE)–Allotex, a Boston based private company developing the TransForm Corneal Allograft (TCA) for the treatment of presbyopia (reading glasses) and hyperopia (far sightedness), is pleased to report that over 50 eyes have been treate…
Riassunto: Il sistema di esame del fondo oculare basato su intelligenza artificiale per la retinopatia diabetica di Eyenuk dimostra prestazioni eccezionali in uno studio clinico registrativo, prospettico e multicentro
LOS ANGELES–(BUSINESS WIRE)–Eyenuk Inc., fornitore globale di tecnologie e servizi medici basati su intelligenza artificiale (IA), nonché leader nelle applicazioni nel mondo reale della tecnologia IA Eye Screening™, ha annunciato oggi i risultati eme…
RadianceTx® Expands Team to Develop Beta Ophthalmic System
TUCSON, Ariz. & LONDON–(BUSINESS WIRE)–Radiance Therapeutics, Inc. (RadianceTx®) is pleased to announce the expansion of its core team: Abigail Mackrill, formerly of Ophthalmology Futures Forums and The Ophthalmologist, joins as Director of Busin…
Eyenuk’s AI Eye Screening System For Diabetic Retinopathy Demonstrates Exceptional Performance In A Prospective, Multi-Center, Pivotal Clinical Trial
LOS ANGELES–(BUSINESS WIRE)–Eyenuk’s AI Eye Screening System For Diabetic Retinopathy Demonstrates Exceptional Performance In A Prospective, Multi-Center, Pivotal Clinical Trial
Global Ophthalmic Knives Market Forecast, 2019 to 2023 – Expansion of Product Portfolio Through Launches of Single-Use Ophthalmic Knives – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Ophthalmic Knives Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering. The ophthalmic knives market will register a CAGR of over 5% by 2023. The expansion of product portfolio through launches of single-use ophthalmic knives will drive the ophthalmic knives market growth in the forthcoming years. The need for ophthalmic knives is increasing with the growing prevalence of ophthalmic diseases such as keratosis, glaucoma, and other opht
Avellino Labs Expands Medical Advisory Board with Internationally-Renown Ophthalmologists
MENLO PARK, Calif.–(BUSINESS WIRE)–Avellino Labs expands medical advisory board with leaders in ophthalmology.
New Data from Phase 3 Teprotumumab Trial (OPTIC) Shows Dramatic Reduction in Proptosis, or Eye Bulging, the Main Cause of Morbidity in Active Thyroid Eye Disease (TED)
DUBLIN–(BUSINESS WIRE)–Horizon announced data from a Phase 3 trial evaluating teprotumumab for active thyroid eye disease, which often occurs in people with Graves’ disease.
SparingVision to Present Preclinical Datas for Retinitis Pigmentaria’s Treatment during Annual Congress of the Association for Research in Vision and Ophthalmology (ARVO)
PARIS–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/biotech?src=hash" target="_blank"gt;#biotechlt;/agt;–SparingVision to present preclinical datas for Retinitis Pigmentaria’s treatment during ARVO.
Santen and Glaukos Enter into Collaboration and Distribution Agreement for Exclusive Distribution of the MicroShunt (DE-128) in the United States
OSAKA, Japan & SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Santen Pharmaceutical Co., Ltd. (“Santen” TSE: 4536) and Glaukos Corporation (“Glaukos” NYSE: GKOS), announced today that Santen’s U.S. subsidiary, Santen Inc., has entered into a multi-year agr…
Alcon to Participate in Bank of America Merrill Lynch and Jefferies Healthcare Conferences
GENEVA–(BUSINESS WIRE)–Alcon to participate in Bank of America Merrill Lynch and Jefferies Healthcare Conferences
Alcon to Participate in Bank of America Merrill Lynch and Jefferies Healthcare Conferences
GENEVA–(BUSINESS WIRE)–Alcon to participate in Bank of America Merrill Lynch and Jefferies Healthcare Conferences